Nonsurgical Treatment for Upper Eyelid Retraction in Patients with Inactive Graves' Orbitopathy

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2023 Jan 1

PMID 36587368

Authors

Sandra Vokurka Topljak

Martina Galiot Delic

Kresimir Mandic

Sanja Peric

Maja Baretic

Jelena Juri Mandic

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the effectiveness of incobotulinumtoxinA (Xeomin) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites.

Methods: This is a comparative, prospective study, conducted at the Department of Ophthalmology, Medical School, University Hospital Centre Zagreb, EUGOGO site (EUropean Group On Graves' Orbitopathy) in Croatia from January 2020 till January of 2021 in accordance with national health headquarter recommendations. All patients were classified as inactive with marked eyelid retraction and randomly divided into groups according to application sites. Group A underwent transconjunctival application (18 eyes) and group B transcutaneous application (20 eyes) of incobotulinumtoxinA. The primary end point of this study was lowering the eyelid, to alleviate anterior eye segment symptoms and achieve acceptable aesthetic appearance until surgery becomes available.

Results: There were no nonresponders and we found no statistically significant difference in the degree of lowering the eyelid between the two application sites. Following rules for avoiding spread of SARS-CoV-19, none of the patients included in this study were infected. Moreover, participants reported diminishing of anterior eye segment irritation and improved aesthetics.

Conclusion: Treatment of inactive GO patients with incobotulinumtoxinA for upper eyelid retraction is efficient and safe and can be used as an adjuvant treatment while patients wait for surgery, by alleviating symptoms and improving the level of aesthetic satisfaction without causing a threat to anterior eye segment and visual function. The study showed that effect of treatment was the same, whether we applied the toxin transconjunctivaly or transcutaneously.

Citing Articles

Synergistic Therapy for Graves' Ophthalmopathy-Associated Eyelid Retraction: Steroid, 5-FU, and Botulinum Neurotoxin a Combination.

Kim Y, Lew H J Clin Med. 2024; 13(10).

PMID: 38792551 PMC: 11121829. DOI: 10.3390/jcm13103012.

An ensemble deep learning diagnostic system for determining Clinical Activity Scores in thyroid-associated ophthalmopathy: integrating multi-view multimodal images from anterior segment slit-lamp photographs and facial images.

Yan C, Zhang Z, Zhang G, Liu H, Zhang R, Liu G Front Endocrinol (Lausanne). 2024; 15:1365350.

PMID: 38628586 PMC: 11019375. DOI: 10.3389/fendo.2024.1365350.

Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.

Yu Y, Hu Y, Lu M, Ouyang Z, Xu M, Zhao L Ophthalmol Ther. 2024; 13(4):1015-1024.

PMID: 38376797 PMC: 10912376. DOI: 10.1007/s40123-024-00892-4.

References

Koornneef L . Eyelid and orbital fascial attachments and their clinical significance. Eye (Lond). 1988; 2 ( Pt 2):130-4. DOI: 10.1038/eye.1988.26. View

Mandic J, Kozmar A, Kusacic-Kuna S, Jazbec A, Mandic K, Mrazovac D . The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis. Graefes Arch Clin Exp Ophthalmol. 2018; 256(4):845-852. DOI: 10.1007/s00417-017-3892-6. View

Ebner R . Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy. J Clin Neuroophthalmol. 1993; 13(4):258-61. View

Biglan A . Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthalmic Surg. 1994; 25(3):186-8. View

Ozkan S, Can D, Soylev M, Arsan A, Duman S . Chemodenervation in treatment of upper eyelid retraction. Ophthalmologica. 1997; 211(6):387-90. DOI: 10.1159/000310837. View

Uddin J, Davies P . Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology. 2002; 109(6):1183-7. DOI: 10.1016/s0161-6420(02)01041-2. View

Dintelmann T, Sold J, Grehn F . [Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease]. Ophthalmologe. 2004; 102(3):247-50. DOI: 10.1007/s00347-004-1091-4. View

Traisk F, Tallstedt L . Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction--a pilot study. Acta Ophthalmol Scand. 2002; 79(6):585-8. DOI: 10.1034/j.1600-0420.2001.790608.x. View

Costa P, Saraiva F, Matayoshi S . [Morphometric analysis of the palpebral fissure in patients with thyroid-related disfunction before and after application of botulinum toxin]. Arq Bras Endocrinol Metabol. 2006; 50(5):920-5. DOI: 10.1590/s0004-27302006000500014. View

10.

Salour H, Bagheri B, Aletaha M, Babsharif B, Kleshadi M, Abrishami M . Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease. Orbit. 2010; 29(2):114-8. DOI: 10.3109/01676830903324268. View

11.

Costa P, Saraiva F, Pereira I, Monteiro M, Matayoshi S . Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye (Lond). 2008; 23(4):767-73. DOI: 10.1038/eye.2008.165. View

12.

Sadiq S, Dharmasena A . Superior rectus underaction following botulinum toxin injection to induce protective upper eye lid ptosis--a comparative study of two techniques. Strabismus. 2014; 22(3):111-4. DOI: 10.3109/09273972.2014.932394. View

13.

Dressler D, Pan L, Bigalke H . Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay. J Neural Transm (Vienna). 2018; 125(9):1351-1354. DOI: 10.1007/s00702-018-1897-x. View

14.

Scaglione F . Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel). 2016; 8(3). PMC: 4810210. DOI: 10.3390/toxins8030065. View

15.

Naumann M, Boo L, Ackerman A, Gallagher C . Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2012; 120(2):275-90. PMC: 3555308. DOI: 10.1007/s00702-012-0893-9. View

16.

Ozgur O, Murariu D, Parsa A, Parsa F . Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention. Hawaii J Med Public Health. 2012; 71(5):120-3. PMC: 3360079. View